These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29250662)

  • 1. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
    Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
    Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
    Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
    Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
    Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
    Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Significance of P53, C-MYC and BCL-6 Abnormality in Patients with Diffuse Large B Cell Lymphoma].
    Chai CG; Zhang JJ; Li N; Cao L; Zhang SY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):89-93. PubMed ID: 26913400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
    Takano Y; Saegusa M; Ikenaga M; Okayasu I
    Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
    Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
    Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
    Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
    Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.
    Suzuki M; Muroi A; Nojima M; Numata A; Takasaki H; Sakai R; Yokose T; Miyagi Y; Koshikawa N
    Proteomics Clin Appl; 2020 Jan; 14(1):e1900091. PubMed ID: 31721454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].
    Weng Y; Gao ZF; Liu K; Zhang WJ; Ke XY; Li M
    Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):681-3. PubMed ID: 16202261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
    Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
    Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.
    Maartense E; Kramer MH; le Cessie S; Kluin-Nelemans JC; Kluin PM; Snijder S; Noordijk EM
    Leuk Lymphoma; 2004 Jan; 45(1):101-7. PubMed ID: 15061204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
    BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience.
    Hu WM; Jin JT; Wu CY; Lu JB; Zhang LH; Zeng J; Lin SX
    Diagn Pathol; 2019 Nov; 14(1):128. PubMed ID: 31711519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].
    Sun GX; Cao XS; Li Q; Wang ZL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Oct; 29(5):576-81. PubMed ID: 23042398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.